Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Senate Judiciary Committee Postpones Votes On Two Federal Court Nominees
Republicans on the Senate Judiciary Committee delayed a confirmation vote on President Obama"s nominees for federal court positions until after the Memorial Day recess, Roll Call reports. David Hamilton, a district court judge in southern Indiana, is nominated for the 7th U.S. Circuit Court of Appeals, and Andre Davis is nominated for the 4th U.S. Circuit Court of Appeals (Brady, Roll Call, 5/21). Committee ranking member Jeff Sessions (R-Ala.) said, "Our members are concerned" about Hamilton, adding that Hamilton "has had a number of troubling rulings dealing with a series of prayers at the Indiana Legislature." Hamilton in 2005 ruled that prayers used to open the Legislature must be nonsectarian. Sessions said he also is concerned about Hamilton"s ruling to prohibit religious displays in public buildings. Committee Chair Patrick Leahy (D-Vt.) defended Hamilton"s record. Leahy said, "He is, after all, the son of a minister, and he believes very strongly in the constitutional separation of church and state" (Stern, Bloomberg/Philadelphia Inquirer, 5/22). Leahy added that Hamilton "ought to be commended rather than obstructed or delayed." Meanwhile, the committee is awaiting Obama"s nominee to replace Justice David Souter on the Supreme Court. The nomination could further complicate consideration of Hamilton and Davis, as it is expected to occupy the panel through the summer (Roll Call, 5/21).

Enzon Commences Phase II Trial Of PEG-SN38
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer.
News of the day
American Lung Association Applauds EPA For Taking Critical Steps To Protect Public Health From Global Shipping Pollution
Statement of Captain Charles D. Connor, U.S. Navy (Ret.), American Lung Association President and CEO:
Public Health

'Death Receptors' Designed To Kill Our Cells May Make Them Stronger

It turns out that from the perspective of cell biology, Nietzsche may have been right after all: that which does not kill us does make us stronger. In a review article published in the June 2009 print issue of The FASEB Journal, scientists from the Mayo Clinic explain how cell receptors (called "death receptors") used by the body to shut down old, diseased, or otherwise unwanted cells (called "apoptosis") may also be used to make cells heartier when facing a wide range of illnesses, from liver disease to cancer. "Increasing our knowledge of how death receptors function will allow us to develop better and more effective therapies for several human diseases," said Gregory J. Gores, M.D., Chair of the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minn., and one of the scientists involved in the work. In their article, Gores and his colleague, Maria Guicciardi, also from the Mayo Clinic, described the various molecular pathways activated by death receptors and the proteins involved in the process. Specifically, they looked at how these proteins interact with each other and how they redistribute within a cell. Death receptors are an essential tool for the immune system to eliminate cells that have been overtaken by viruses, undergone potentially harmful genetic modifications, or have become too old to function properly. Understanding the exact sequence of events that occurs after death receptors are activated, including identifying key proteins involved in the processes, may allow researchers to develop entirely new therapeutics. These therapeutics not only would give doctors the ability to choose when and if certain cells are taken out of service, but they would also give doctors the ability to trigger cells to shift into "survival mode." "As far as names are concerned, nothing in biology sounds more intimidating than "death receptors,"" said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Fortunately for us, when scientists look at the intricate machinery of how cells die, they dig up clues to longer, healthier lives." Details: Maria Eugenia Guicciardi and Gregory J. Gores. Life and death by death receptors. FASEB J. 2009 23: 1625-1637. http://www.fasebj.org/cgi/content/abstract/23/6/1625 Cody Mooneyhan Federation of American Societies for Experimental Biology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009